These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29959729)

  • 21. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.
    Elias-Sonnenschein LS; Helisalmi S; Natunen T; Hall A; Paajanen T; Herukka SK; Laitinen M; Remes AM; Koivisto AM; Mattila KM; Lehtimäki T; Verhey FR; Visser PJ; Soininen H; Hiltunen M
    PLoS One; 2013; 8(4):e59676. PubMed ID: 23573206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease.
    Mattsson N; Insel P; Tosun D; Zhang J; Jack CR; Galasko D; Weiner M;
    PLoS One; 2013; 8(12):e85443. PubMed ID: 24392009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association Between Common Variants of APOE, ABCA7, A2M, BACE1, and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: Data from the PUMCH Dementia Cohort.
    Dong L; Mao C; Liu C; Li J; Huang X; Wang J; Lei D; Chu S; Sha L; Xu Q; Peng B; Cui L; Gao J
    J Alzheimers Dis; 2022; 85(4):1511-1518. PubMed ID: 34958020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Mediating Role of Inflammation in the Relationship Between α-Synuclein and Cognitive Functioning.
    Dabiri S; Ramírez Ruiz MI; Jean-Louis G; Ntekim OE; Obisesan TO; Campbell AL; Mwendwa DT;
    J Gerontol A Biol Sci Med Sci; 2023 Feb; 78(2):206-212. PubMed ID: 36269624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF.
    Boiten WA; van Steenoven I; Xiao MF; Worley PF; Noli B; Cocco C; Ferri GL; Lemstra AW; Teunissen CE
    Cells; 2020 Dec; 10(1):. PubMed ID: 33383752
    [No Abstract]   [Full Text] [Related]  

  • 31. Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels.
    Ibanez L; Dube U; Saef B; Budde J; Black K; Medvedeva A; Del-Aguila JL; Davis AA; Perlmutter JS; Harari O; Benitez BA; Cruchaga C
    BMC Neurol; 2017 Nov; 17(1):198. PubMed ID: 29141588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genome-Wide Association Analysis across Endophenotypes in Alzheimer's Disease: Main Effects and Disease Stage-Specific Interactions.
    Rosewood TJ; Nho K; Risacher SL; Gao S; Shen L; Foroud T; Saykin AJ; On Behalf Of The Alzheimer's Disease Neuroimaging Initiative
    Genes (Basel); 2023 Oct; 14(11):. PubMed ID: 38002954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.
    Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J
    Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of CSF α-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.
    García-Ayllón MS; Monge-Argilés JA; Monge-García V; Navarrete F; Cortés-Gómez MA; Sánchez-Payá J; Manzanares J; Gasparini-Berenguer R; Leiva-Santana C; Sáez-Valero J
    J Neurochem; 2019 Jul; 150(2):218-230. PubMed ID: 31077373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alzheimer's disease susceptibility locus in CD2AP is associated with increased cerebrospinal fluid tau levels in mild cognitive impairment.
    Xue YY; Chen YH; Lin RR; Huang HF; Wu ZY; Tao QQ;
    Neurosci Lett; 2022 Feb; 771():136419. PubMed ID: 34958910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between NME8 locus polymorphism and cognitive decline, cerebrospinal fluid and neuroimaging biomarkers in Alzheimer's disease.
    Liu Y; Yu JT; Wang HF; Hao XK; Yang YF; Jiang T; Zhu XC; Cao L; Zhang DQ; Tan L
    PLoS One; 2014; 9(12):e114777. PubMed ID: 25486118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
    Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
    Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variations in the FRA10AC1 Fragile Site and 15q21 Are Associated with Cerebrospinal Fluid Aβ1-42 Level.
    Li QS; Parrado AR; Samtani MN; Narayan VA;
    PLoS One; 2015; 10(8):e0134000. PubMed ID: 26252872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.
    Calderón-Garcidueñas L; Avila-Ramírez J; Calderón-Garcidueñas A; González-Heredia T; Acuña-Ayala H; Chao CK; Thompson C; Ruiz-Ramos R; Cortés-González V; Martínez-Martínez L; García-Pérez MA; Reis J; Mukherjee PS; Torres-Jardón R; Lachmann I
    J Alzheimers Dis; 2016 Sep; 54(2):597-613. PubMed ID: 27567860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.